Skip to main content
Top
Published in: Tumor Biology 10/2016

01-10-2016 | Review

Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures

Authors: Olga Golubnitschaja, Manuel Debald, Kristina Yeghiazaryan, Walther Kuhn, Martin Pešta, Vincenzo Costigliola, Godfrey Grech

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

Rapidly increasing incidence of breast cancer is a new social challenge resulting from a spectrum of internal and external risk factors which appear to be well accepted as an attribute of the early twenty-first century, being, however, new for female sub-populations compared to the past. These include altered socio-economical conditions such as occupational exposure, rotating shift work, specific environmental factors (increased pollution and environmental toxicity, altered dietary habits, quality and composition of meal) as well as consequently shifted and/or adapted physiologic factors such as lower age at menarche, late age of first full-term pregnancy, if any, shorter periods of breastfeeding and later menopause. Consolidated expert statements suggest that over 50 % of all breast cancer cases may be potentially prevented by risk reduction strategy such as regulation of modifiable risk factors. Currently available risk assessment models may estimate potential breast cancer predisposition, in general; however, they are not able to predict the disease manifestation individually. Further, current deficits in risk assessment and effective breast cancer prevention have been recently investigated and summarised as follows: gaps in risk estimation, preventive therapy, lifestyle prevention, understanding of the biology of breast cancer risk and implementation of known preventive measures. This paper overviews the most relevant risk factors, provides recommendations for improved risk assessment and proposes an extended questionnaire for effective preventive measures.
Literature
1.
go back to reference Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J. 2013;4(1):6.PubMedPubMedCentralCrossRef Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J. 2013;4(1):6.PubMedPubMedCentralCrossRef
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
3.
go back to reference Leung GM, Thach TQ, Lam T-H, Hedley AJ, Foo W, Fielding R, et al. Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. Br J Cancer. 2002;87(9):982–8.PubMedPubMedCentralCrossRef Leung GM, Thach TQ, Lam T-H, Hedley AJ, Foo W, Fielding R, et al. Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. Br J Cancer. 2002;87(9):982–8.PubMedPubMedCentralCrossRef
4.
go back to reference Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005;34(2):405–12.PubMedCrossRef Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005;34(2):405–12.PubMedCrossRef
5.
go back to reference Jung YS, Na KY, Kim KS, Ahn S-H, Lee SJ, Lee S-J, et al. Nation-wide Korean breast cancer data from 2008 using the breast cancer registration program. J Breast Cancer. 2011;14(3):229–36.PubMedPubMedCentralCrossRef Jung YS, Na KY, Kim KS, Ahn S-H, Lee SJ, Lee S-J, et al. Nation-wide Korean breast cancer data from 2008 using the breast cancer registration program. J Breast Cancer. 2011;14(3):229–36.PubMedPubMedCentralCrossRef
6.
go back to reference Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, et al. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16(5):446.PubMedPubMedCentralCrossRef Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, et al. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16(5):446.PubMedPubMedCentralCrossRef
7.
go back to reference Girotra S, Yeghiazaryan K, Golubnitschaja O. Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics. Pers Med. 2016; in press. Girotra S, Yeghiazaryan K, Golubnitschaja O. Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics. Pers Med. 2016; in press.
8.
go back to reference Lemke HU, Golubnitschaja O. Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within ‘horizon 2020’. EPMA J. 2014;5(1):8.PubMedPubMedCentralCrossRef Lemke HU, Golubnitschaja O. Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within ‘horizon 2020’. EPMA J. 2014;5(1):8.PubMedPubMedCentralCrossRef
9.
go back to reference Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomark Prev. 1995;4(5):567–71. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomark Prev. 1995;4(5):567–71.
10.
go back to reference Liu Y, Colditz GA, Rosner B, Berkey CS, Collins LC, Schnitt SJ, et al. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. J Natl Cancer Inst. 2013;105(20):1571–8.PubMedPubMedCentralCrossRef Liu Y, Colditz GA, Rosner B, Berkey CS, Collins LC, Schnitt SJ, et al. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. J Natl Cancer Inst. 2013;105(20):1571–8.PubMedPubMedCentralCrossRef
11.
go back to reference Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, et al. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide. Breast Cancer Res Treat. 2013;142(3):569–78.PubMedCrossRef Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, et al. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide. Breast Cancer Res Treat. 2013;142(3):569–78.PubMedCrossRef
12.
go back to reference Komm BS, Mirkin S. An overview of current and emerging SERMs. J Steroid Biochem Mol Biol. 2014;143:207–22.PubMedCrossRef Komm BS, Mirkin S. An overview of current and emerging SERMs. J Steroid Biochem Mol Biol. 2014;143:207–22.PubMedCrossRef
13.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360(9328):187–95.CrossRef Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360(9328):187–95.CrossRef
14.
go back to reference Ballard-Barbash R, Hunsberger S, Alciati MH, Blair SN, Goodwin PJ, McTiernan A, et al. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst. 2009;101(9):630–43.PubMedPubMedCentralCrossRef Ballard-Barbash R, Hunsberger S, Alciati MH, Blair SN, Goodwin PJ, McTiernan A, et al. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst. 2009;101(9):630–43.PubMedPubMedCentralCrossRef
15.
16.
go back to reference Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, et al. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. Breast Cancer Res Treat. 2012;133(1):127–35.PubMedCrossRef Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, et al. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. Breast Cancer Res Treat. 2012;133(1):127–35.PubMedCrossRef
17.
go back to reference Rubinstein WS, O’neill SM, Rothrock N, Starzyk EJ, Beaumont JL, Acheson LS, et al. Components of family history associated with women’s disease perceptions for cancer: a report from the Family Healthware™ Impact Trial. Genitourin Med. 2011;13(1):52–62.CrossRef Rubinstein WS, O’neill SM, Rothrock N, Starzyk EJ, Beaumont JL, Acheson LS, et al. Components of family history associated with women’s disease perceptions for cancer: a report from the Family Healthware™ Impact Trial. Genitourin Med. 2011;13(1):52–62.CrossRef
18.
go back to reference Randall TC, Armstrong K. Health care disparities in hereditary ovarian cancer: are we reaching the underserved population? Curr Treat Options in Oncol. 2016;17(8):39.CrossRef Randall TC, Armstrong K. Health care disparities in hereditary ovarian cancer: are we reaching the underserved population? Curr Treat Options in Oncol. 2016;17(8):39.CrossRef
19.
go back to reference Alford SH, Leadbetter S, Rodriguez JL, Hawkins NA, Scholl LE, Peipins LA. Cancer screening among a population-based sample of insured women. Prev Med Rep. 2015;2:15–20.PubMedCrossRef Alford SH, Leadbetter S, Rodriguez JL, Hawkins NA, Scholl LE, Peipins LA. Cancer screening among a population-based sample of insured women. Prev Med Rep. 2015;2:15–20.PubMedCrossRef
21.
go back to reference Heikkilä K, Nyberg ST, Theorell T, Fransson EI, Alfredsson L, Bjorner JB, et al. Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116,000 European men and women. BMJ. 2013;346:f165.PubMedPubMedCentralCrossRef Heikkilä K, Nyberg ST, Theorell T, Fransson EI, Alfredsson L, Bjorner JB, et al. Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116,000 European men and women. BMJ. 2013;346:f165.PubMedPubMedCentralCrossRef
22.
go back to reference Fazzo L, Carere M, Tisano F, Bruno C, Cernigliaro A, Cicero MR, et al. Cancer incidence in Priolo, Sicily: a spatial approach for estimation of industrial air pollution impact. Geospat Health. 2016;11(1):320.PubMedCrossRef Fazzo L, Carere M, Tisano F, Bruno C, Cernigliaro A, Cicero MR, et al. Cancer incidence in Priolo, Sicily: a spatial approach for estimation of industrial air pollution impact. Geospat Health. 2016;11(1):320.PubMedCrossRef
23.
go back to reference Zimeri AM, Robb SW, Hassan SM, Hire RR, Davis MB. Assessing heavy metal and PCB exposure from tap water by measuring levels in plasma from sporadic breast cancer patients, a pilot study. Int J Environ Res Public Health. 2015;12(12):15683–91.PubMedPubMedCentralCrossRef Zimeri AM, Robb SW, Hassan SM, Hire RR, Davis MB. Assessing heavy metal and PCB exposure from tap water by measuring levels in plasma from sporadic breast cancer patients, a pilot study. Int J Environ Res Public Health. 2015;12(12):15683–91.PubMedPubMedCentralCrossRef
24.
go back to reference Alatise OI, Schrauzer GN. Lead exposure: a contributing cause of the current breast cancer epidemic in Nigerian women. Biol Trace Elem Res. 2010;136(2):127–39.PubMedPubMedCentralCrossRef Alatise OI, Schrauzer GN. Lead exposure: a contributing cause of the current breast cancer epidemic in Nigerian women. Biol Trace Elem Res. 2010;136(2):127–39.PubMedPubMedCentralCrossRef
25.
go back to reference Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40.PubMedPubMedCentralCrossRef Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40.PubMedPubMedCentralCrossRef
26.
go back to reference Little MP, McElvenny DM. Male breast cancer incidence and mortality risk in the Japanese atomic bomb survivors—differences in excess relative and absolute risk from female breast cancer. Environ Health Perspect. 2016. doi:10.1289/EHP151. PubMed Little MP, McElvenny DM. Male breast cancer incidence and mortality risk in the Japanese atomic bomb survivors—differences in excess relative and absolute risk from female breast cancer. Environ Health Perspect. 2016. doi:10.​1289/​EHP151.​ PubMed
27.
go back to reference White AJ, Bradshaw PT, Herring AH, Teitelbaum SL, Beyea J, Stellman SD, et al. Exposure to multiple sources of polycyclic aromatic hydrocarbons and breast cancer incidence. Environ Int. 2016;89–90:185–92.PubMedCrossRef White AJ, Bradshaw PT, Herring AH, Teitelbaum SL, Beyea J, Stellman SD, et al. Exposure to multiple sources of polycyclic aromatic hydrocarbons and breast cancer incidence. Environ Int. 2016;89–90:185–92.PubMedCrossRef
29.
go back to reference Kotepui M. Diet and risk of breast cancer. Contemp Oncol Pozn Pol. 2016;20(1):13–9. Kotepui M. Diet and risk of breast cancer. Contemp Oncol Pozn Pol. 2016;20(1):13–9.
30.
go back to reference Seitz HK, Pelucchi C, Bagnardi V, La Vecchia C. Epidemiology and pathophysiology of alcohol and breast cancer: update 2012. Alcohol Alcohol. 2012;47(3):204–12.PubMedCrossRef Seitz HK, Pelucchi C, Bagnardi V, La Vecchia C. Epidemiology and pathophysiology of alcohol and breast cancer: update 2012. Alcohol Alcohol. 2012;47(3):204–12.PubMedCrossRef
31.
go back to reference Cebioglu M, Schild H, Golubnitschaja O. Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J. 2010;1(1):130–7.PubMedPubMedCentralCrossRef Cebioglu M, Schild H, Golubnitschaja O. Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J. 2010;1(1):130–7.PubMedPubMedCentralCrossRef
32.
go back to reference Zambacos GJ, Molnar C, Mandrekas AD. Silicone lymphadenopathy after breast augmentation: case reports, review of the literature, and current thoughts. Aesthet Plast Surg. 2013;37(2):278–89.CrossRef Zambacos GJ, Molnar C, Mandrekas AD. Silicone lymphadenopathy after breast augmentation: case reports, review of the literature, and current thoughts. Aesthet Plast Surg. 2013;37(2):278–89.CrossRef
33.
go back to reference Ozkaya N, Grogg KL, Dogan A. Seroma-associated anaplastic large cell lymphoma arising in the background of subcutaneous calcinosis: beyond breast implants. Histopathology. 2016. doi:10.1111/his.13012. Ozkaya N, Grogg KL, Dogan A. Seroma-associated anaplastic large cell lymphoma arising in the background of subcutaneous calcinosis: beyond breast implants. Histopathology. 2016. doi:10.​1111/​his.​13012.​
34.
go back to reference Favia G, Tempesta A, Limongelli L, Crincoli V, Piattelli A, Maiorano E. Metastatic breast cancer in medication-related osteonecrosis around mandibular implants. Am J Case Rep. 2015;16:621–6.PubMedPubMedCentralCrossRef Favia G, Tempesta A, Limongelli L, Crincoli V, Piattelli A, Maiorano E. Metastatic breast cancer in medication-related osteonecrosis around mandibular implants. Am J Case Rep. 2015;16:621–6.PubMedPubMedCentralCrossRef
35.
go back to reference Bhandari S, Rattan V, Panda N, Vaiphei K, Mittal BR. Oral cancer or periimplantitis: a clinical dilemma. J Prosthet Dent. 2016;115(6):658–61.PubMedCrossRef Bhandari S, Rattan V, Panda N, Vaiphei K, Mittal BR. Oral cancer or periimplantitis: a clinical dilemma. J Prosthet Dent. 2016;115(6):658–61.PubMedCrossRef
36.
go back to reference Monsees GM, Kraft P, Hankinson SE, Hunter DJ, Schernhammer ES. Circadian genes and breast cancer susceptibility in rotating shift workers. Int J Cancer. 2012;131(11):2547–52.PubMedPubMedCentralCrossRef Monsees GM, Kraft P, Hankinson SE, Hunter DJ, Schernhammer ES. Circadian genes and breast cancer susceptibility in rotating shift workers. Int J Cancer. 2012;131(11):2547–52.PubMedPubMedCentralCrossRef
37.
go back to reference Rafnsson V, Tulinius H, Jónasson JG, Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control. 2001;12(2):95–101.PubMedCrossRef Rafnsson V, Tulinius H, Jónasson JG, Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control. 2001;12(2):95–101.PubMedCrossRef
38.
go back to reference Schubauer-Berigan MK, Anderson JL, Hein MJ, Little MP, Sigurdson AJ, Pinkerton LE. Breast cancer incidence in a cohort of U.S. flight attendants. Am J Ind Med. 2015;58(3):252–66.PubMedPubMedCentralCrossRef Schubauer-Berigan MK, Anderson JL, Hein MJ, Little MP, Sigurdson AJ, Pinkerton LE. Breast cancer incidence in a cohort of U.S. flight attendants. Am J Ind Med. 2015;58(3):252–66.PubMedPubMedCentralCrossRef
39.
go back to reference Pudrovska T, Carr D, McFarland M, Collins C. Higher-status occupations and breast cancer: a life-course stress approach. Soc Sci Med 1982. 2013;89:53–61. Pudrovska T, Carr D, McFarland M, Collins C. Higher-status occupations and breast cancer: a life-course stress approach. Soc Sci Med 1982. 2013;89:53–61.
40.
go back to reference Härmä M, Kecklund G. Shift work and health—how to proceed? Scand J Work Environ Health. 2010;36(2):81–4.PubMedCrossRef Härmä M, Kecklund G. Shift work and health—how to proceed? Scand J Work Environ Health. 2010;36(2):81–4.PubMedCrossRef
41.
go back to reference Wang X-S, Armstrong MEG, Cairns BJ, Key TJ, Travis RC. Shift work and chronic disease: the epidemiological evidence. Occup Med (Lond). 2011;61(2):78–89.CrossRef Wang X-S, Armstrong MEG, Cairns BJ, Key TJ, Travis RC. Shift work and chronic disease: the epidemiological evidence. Occup Med (Lond). 2011;61(2):78–89.CrossRef
42.
go back to reference Richter K, Acker J, Kamcev N, Bajraktarov S, Piehl A, Niklewski G. Recommendations for the prevention of breast cancer in shift workers. EPMA J. 2011;2(4):351–6.PubMedPubMedCentralCrossRef Richter K, Acker J, Kamcev N, Bajraktarov S, Piehl A, Niklewski G. Recommendations for the prevention of breast cancer in shift workers. EPMA J. 2011;2(4):351–6.PubMedPubMedCentralCrossRef
43.
go back to reference Costa G, Haus E, Stevens R. Shift work and cancer—considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health. 2010;36(2):163–79.PubMedCrossRef Costa G, Haus E, Stevens R. Shift work and cancer—considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health. 2010;36(2):163–79.PubMedCrossRef
44.
go back to reference Pijpe A, Slottje P, van Pelt C, Stehmann F, Kromhout H, van Leeuwen FE, et al. The Nightingale study: rationale, study design and baseline characteristics of a prospective cohort study on shift work and breast cancer risk among nurses. BMC Cancer. 2014;14:47.PubMedPubMedCentralCrossRef Pijpe A, Slottje P, van Pelt C, Stehmann F, Kromhout H, van Leeuwen FE, et al. The Nightingale study: rationale, study design and baseline characteristics of a prospective cohort study on shift work and breast cancer risk among nurses. BMC Cancer. 2014;14:47.PubMedPubMedCentralCrossRef
45.
go back to reference Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses’ Health Study. J Natl Cancer Inst. 2001;93(20):1563–8.PubMedCrossRef Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses’ Health Study. J Natl Cancer Inst. 2001;93(20):1563–8.PubMedCrossRef
46.
go back to reference Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2005;41(13):2023–32.PubMedCrossRef Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2005;41(13):2023–32.PubMedCrossRef
47.
go back to reference Hansen J. Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control. 2006;17(4):531–7.PubMedCrossRef Hansen J. Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control. 2006;17(4):531–7.PubMedCrossRef
48.
go back to reference Fritschi L, Glass DC, Heyworth JS, Aronson K, Girschik J, Boyle T, et al. Hypotheses for mechanisms linking shiftwork and cancer. Med Hypotheses. 2011;77(3):430–6.PubMedCrossRef Fritschi L, Glass DC, Heyworth JS, Aronson K, Girschik J, Boyle T, et al. Hypotheses for mechanisms linking shiftwork and cancer. Med Hypotheses. 2011;77(3):430–6.PubMedCrossRef
49.
go back to reference Linnersjö A, Hammar N, Dammström B-G, Johansson M, Eliasch H. Cancer incidence in airline cabin crew: experience from Sweden. Occup Environ Med. 2003;60(11):810–4.PubMedPubMedCentralCrossRef Linnersjö A, Hammar N, Dammström B-G, Johansson M, Eliasch H. Cancer incidence in airline cabin crew: experience from Sweden. Occup Environ Med. 2003;60(11):810–4.PubMedPubMedCentralCrossRef
50.
go back to reference Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743–53.PubMed Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743–53.PubMed
51.
go back to reference Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer. 2002;38(1):27–43.PubMedCrossRef Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer. 2002;38(1):27–43.PubMedCrossRef
52.
go back to reference Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Nat Cancer Ins Monogr. 2004;(32):40–50. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Nat Cancer Ins Monogr. 2004;(32):40–50.
55.
go back to reference Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919–25.PubMedCrossRef Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919–25.PubMedCrossRef
56.
go back to reference Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8(11):887–99.PubMedCrossRef Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8(11):887–99.PubMedCrossRef
57.
go back to reference Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425–30.PubMedCrossRef Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425–30.PubMedCrossRef
58.
go back to reference Verkasalo PK, Lillberg K, Stevens RG, Hublin C, Partinen M, Koskenvuo M, et al. Sleep duration and breast cancer: a prospective cohort study. Cancer Res. 2005;65(20):9595–600.PubMedCrossRef Verkasalo PK, Lillberg K, Stevens RG, Hublin C, Partinen M, Koskenvuo M, et al. Sleep duration and breast cancer: a prospective cohort study. Cancer Res. 2005;65(20):9595–600.PubMedCrossRef
59.
go back to reference Girschik J, Heyworth J, Fritschi L. Self-reported sleep duration, sleep quality, and breast cancer risk in a population-based case-control study. Am J Epidemiol. 2013;177(4):316–27.PubMedCrossRef Girschik J, Heyworth J, Fritschi L. Self-reported sleep duration, sleep quality, and breast cancer risk in a population-based case-control study. Am J Epidemiol. 2013;177(4):316–27.PubMedCrossRef
60.
go back to reference Vogtmann E, Levitan EB, Hale L, Shikany JM, Shah NA, Endeshaw Y, et al. Association between sleep and breast cancer incidence among postmenopausal women in the Women’s Health Initiative. Sleep. 2013;36(10):1437–44.PubMedPubMedCentral Vogtmann E, Levitan EB, Hale L, Shikany JM, Shah NA, Endeshaw Y, et al. Association between sleep and breast cancer incidence among postmenopausal women in the Women’s Health Initiative. Sleep. 2013;36(10):1437–44.PubMedPubMedCentral
61.
go back to reference Fortner BV, Stepanski EJ, Wang SC, Kasprowicz S, Durrence HH. Sleep and quality of life in breast cancer patients. J Pain Symptom Manag. 2002;24(5):471–80.CrossRef Fortner BV, Stepanski EJ, Wang SC, Kasprowicz S, Durrence HH. Sleep and quality of life in breast cancer patients. J Pain Symptom Manag. 2002;24(5):471–80.CrossRef
62.
go back to reference Ancoli-Israel S, Liu L, Marler MR, Parker BA, Jones V, Sadler GR, et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer. 2006;14(3):201–9.PubMedCrossRef Ancoli-Israel S, Liu L, Marler MR, Parker BA, Jones V, Sadler GR, et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer. 2006;14(3):201–9.PubMedCrossRef
64.
go back to reference Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522(7554):106–10.PubMedPubMedCentralCrossRef Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522(7554):106–10.PubMedPubMedCentralCrossRef
65.
go back to reference Golubnitschaja O, Debald M, Kuhn W, Yeghiazaryan K, Bubnov RV, Goncharenko VM, et al. Flammer syndrome and potential formation of pre-metastatic niches: a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease. EPMA J. 2016;7(Suppl 1):A25. Golubnitschaja O, Debald M, Kuhn W, Yeghiazaryan K, Bubnov RV, Goncharenko VM, et al. Flammer syndrome and potential formation of pre-metastatic niches: a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease. EPMA J. 2016;7(Suppl 1):A25.
69.
go back to reference Yeghiazaryan K, Flammer J, Golubnitschaja O. Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J. 2010;1(2):263–72.PubMedPubMedCentralCrossRef Yeghiazaryan K, Flammer J, Golubnitschaja O. Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J. 2010;1(2):263–72.PubMedPubMedCentralCrossRef
70.
go back to reference Golubnitschaja O, Yeghiazaryan K, Flammer J. Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible? EPMA J. 2010;1(2):237–44.PubMedPubMedCentralCrossRef Golubnitschaja O, Yeghiazaryan K, Flammer J. Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible? EPMA J. 2010;1(2):237–44.PubMedPubMedCentralCrossRef
71.
go back to reference Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377(9765):557–67.PubMedPubMedCentralCrossRef Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377(9765):557–67.PubMedPubMedCentralCrossRef
72.
go back to reference Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815–25.PubMedCrossRef Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815–25.PubMedCrossRef
73.
go back to reference Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff Proj Hope. 2009;28(5):w822–31.CrossRef Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff Proj Hope. 2009;28(5):w822–31.CrossRef
74.
go back to reference Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis. Int J Cancer. 2009;124(3):698–712.PubMedCrossRef Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis. Int J Cancer. 2009;124(3):698–712.PubMedCrossRef
75.
go back to reference Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14.PubMedPubMedCentralCrossRef Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14.PubMedPubMedCentralCrossRef
76.
go back to reference Hilakivi-Clarke L, Forsén T, Eriksson JG, Luoto R, Tuomilehto J, Osmond C, et al. Tallness and overweight during childhood have opposing effects on breast cancer risk. Br J Cancer. 2001;85(11):1680–4.PubMedPubMedCentralCrossRef Hilakivi-Clarke L, Forsén T, Eriksson JG, Luoto R, Tuomilehto J, Osmond C, et al. Tallness and overweight during childhood have opposing effects on breast cancer risk. Br J Cancer. 2001;85(11):1680–4.PubMedPubMedCentralCrossRef
77.
go back to reference Baer HJ, Tworoger SS, Hankinson SE, Willett WC. Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol. 2010;171(11):1183–94.PubMedPubMedCentralCrossRef Baer HJ, Tworoger SS, Hankinson SE, Willett WC. Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol. 2010;171(11):1183–94.PubMedPubMedCentralCrossRef
78.
go back to reference Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, et al. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status—the Japan public health center-based prospective study. Int J Cancer. 2011;129(5):1214–24.PubMedCrossRef Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, et al. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status—the Japan public health center-based prospective study. Int J Cancer. 2011;129(5):1214–24.PubMedCrossRef
79.
go back to reference Robinson WR, Tse CK, Olshan AF, Troester MA. Body size across the life course and risk of premenopausal and postmenopausal breast cancer in black women, the Carolina Breast Cancer Study, 1993-2001. Cancer Causes Control. 2014;25(9):1101–17.PubMedPubMedCentralCrossRef Robinson WR, Tse CK, Olshan AF, Troester MA. Body size across the life course and risk of premenopausal and postmenopausal breast cancer in black women, the Carolina Breast Cancer Study, 1993-2001. Cancer Causes Control. 2014;25(9):1101–17.PubMedPubMedCentralCrossRef
80.
go back to reference Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014;36:114–36.PubMedPubMedCentralCrossRef Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014;36:114–36.PubMedPubMedCentralCrossRef
81.
go back to reference Cebioglu M, Schild HH, Golubnitschaja O. Diabetes mellitus as a risk factor for cancer: is predictive diagnosis possible? In: Golubnitschaja O, editor. Predictive diagnostics and personalized treatment: dream or reality? New York: Nova Science Publishers Inc; 2009. p. 247–62. Cebioglu M, Schild HH, Golubnitschaja O. Diabetes mellitus as a risk factor for cancer: is predictive diagnosis possible? In: Golubnitschaja O, editor. Predictive diagnostics and personalized treatment: dream or reality? New York: Nova Science Publishers Inc; 2009. p. 247–62.
82.
go back to reference Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107(9):1608–17.PubMedPubMedCentralCrossRef Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107(9):1608–17.PubMedPubMedCentralCrossRef
83.
go back to reference Wu AH, Kurian AW, Kwan ML, John EM, Lu Y, Keegan THM, et al. Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC). Cancer Epidemiol Biomark Prev. 2015;24(2):361–8.CrossRef Wu AH, Kurian AW, Kwan ML, John EM, Lu Y, Keegan THM, et al. Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC). Cancer Epidemiol Biomark Prev. 2015;24(2):361–8.CrossRef
84.
go back to reference Bodai BI, Tuso P. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J. 2015;19(2):48–79.PubMedPubMedCentralCrossRef Bodai BI, Tuso P. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J. 2015;19(2):48–79.PubMedPubMedCentralCrossRef
85.
go back to reference Pronk NP, Anderson LH, Crain AL, Martinson BC, O’Connor PJ, Sherwood NE, et al. Meeting recommendations for multiple healthy lifestyle factors. Prevalence, clustering, and predictors among adolescent, adult, and senior health plan members. Am J Prev Med. 2004;27(2 Suppl):25–33.PubMedCrossRef Pronk NP, Anderson LH, Crain AL, Martinson BC, O’Connor PJ, Sherwood NE, et al. Meeting recommendations for multiple healthy lifestyle factors. Prevalence, clustering, and predictors among adolescent, adult, and senior health plan members. Am J Prev Med. 2004;27(2 Suppl):25–33.PubMedCrossRef
86.
go back to reference Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst. 2009;101(6):384–98.PubMedPubMedCentralCrossRef Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst. 2009;101(6):384–98.PubMedPubMedCentralCrossRef
87.
go back to reference Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, et al. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res. 2008;10(2):R26.PubMedPubMedCentralCrossRef Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, et al. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res. 2008;10(2):R26.PubMedPubMedCentralCrossRef
88.
go back to reference Janz KF, Dawson JD, Mahoney LT. Tracking physical fitness and physical activity from childhood to adolescence: the muscatine study. Med Sci Sports Exerc. 2000;32(7):1250–7.PubMedCrossRef Janz KF, Dawson JD, Mahoney LT. Tracking physical fitness and physical activity from childhood to adolescence: the muscatine study. Med Sci Sports Exerc. 2000;32(7):1250–7.PubMedCrossRef
89.
go back to reference Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens. 1995;8(7):657–65.PubMedCrossRef Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens. 1995;8(7):657–65.PubMedCrossRef
90.
go back to reference Guo SS, Huang C, Maynard LM, Demerath E, Towne B, Chumlea WC, et al. Body mass index during childhood, adolescence and young adulthood in relation to adult overweight and adiposity: the Fels Longitudinal Study. Int J Obes Relat Metab Disord. 2000;24(12):1628–35.PubMedCrossRef Guo SS, Huang C, Maynard LM, Demerath E, Towne B, Chumlea WC, et al. Body mass index during childhood, adolescence and young adulthood in relation to adult overweight and adiposity: the Fels Longitudinal Study. Int J Obes Relat Metab Disord. 2000;24(12):1628–35.PubMedCrossRef
91.
go back to reference Nicklas TA, von Duvillard SP, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to dyslipidemia in adults: the Bogalusa Heart Study. Int J Sports Med. 2002;23(Suppl 1):S39–43.PubMedCrossRef Nicklas TA, von Duvillard SP, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to dyslipidemia in adults: the Bogalusa Heart Study. Int J Sports Med. 2002;23(Suppl 1):S39–43.PubMedCrossRef
92.
go back to reference Canadian Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases. The role of the cardiovascular specialist. Can J Cardiol. 1999;15(Suppl G):1G–119G. Canadian Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases. The role of the cardiovascular specialist. Can J Cardiol. 1999;15(Suppl G):1G–119G.
93.
go back to reference Raitakari OT, Porkka KV, Räsänen L, Viikari JS. Relations of life-style with lipids, blood pressure and insulin in adolescents and young adults. The Cardiovascular Risk in Young Finns Study. Atherosclerosis. 1994;111(2):237–46.PubMedCrossRef Raitakari OT, Porkka KV, Räsänen L, Viikari JS. Relations of life-style with lipids, blood pressure and insulin in adolescents and young adults. The Cardiovascular Risk in Young Finns Study. Atherosclerosis. 1994;111(2):237–46.PubMedCrossRef
94.
go back to reference Bergström E, Hernell O, Persson LA. Cardiovascular risk indicators cluster in girls from families of low socio-economic status. Acta Paediatr Oslo Nor 1992. 1996;85(9):1083–90. Bergström E, Hernell O, Persson LA. Cardiovascular risk indicators cluster in girls from families of low socio-economic status. Acta Paediatr Oslo Nor 1992. 1996;85(9):1083–90.
95.
go back to reference Pate RR, Heath GW, Dowda M, Trost SG. Associations between physical activity and other health behaviors in a representative sample of US adolescents. Am J Public Health. 1996;86(11):1577–81.PubMedPubMedCentralCrossRef Pate RR, Heath GW, Dowda M, Trost SG. Associations between physical activity and other health behaviors in a representative sample of US adolescents. Am J Public Health. 1996;86(11):1577–81.PubMedPubMedCentralCrossRef
96.
go back to reference McKenna M, Taylor W, Marks J, Koplan J. Current issues and challenges in chronic disease control. In: Brownson R, Remington P, Davis J, editors. Chronic disease epidemiology and control. Washington DC: United Book; 1998. McKenna M, Taylor W, Marks J, Koplan J. Current issues and challenges in chronic disease control. In: Brownson R, Remington P, Davis J, editors. Chronic disease epidemiology and control. Washington DC: United Book; 1998.
97.
go back to reference Golubnitschaja O. Changing long-held beliefs is never easy: a proposal for multimodal approaches in female healthcare—an integrative view. In: Costigliola V, editor. Healthcare overview: new perspectives. vol. 1. Dordrecht: Springer; 2012. p. 251–68. Golubnitschaja O. Changing long-held beliefs is never easy: a proposal for multimodal approaches in female healthcare—an integrative view. In: Costigliola V, editor. Healthcare overview: new perspectives. vol. 1. Dordrecht: Springer; 2012. p. 251–68.
99.
go back to reference Eleftheriadou A, Chalastras T, Ferekidou E, Yiotakis I, Kyriou L, Tzagarakis M, et al. Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine. Anticancer Res. 2006;26(3B):2345–8.PubMed Eleftheriadou A, Chalastras T, Ferekidou E, Yiotakis I, Kyriou L, Tzagarakis M, et al. Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine. Anticancer Res. 2006;26(3B):2345–8.PubMed
101.
go back to reference Keshteli AH, Baracos VE, Madsen KL. Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: a review. World J Gastroenterol. 2015;21(4):1081–90.PubMedPubMedCentralCrossRef Keshteli AH, Baracos VE, Madsen KL. Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: a review. World J Gastroenterol. 2015;21(4):1081–90.PubMedPubMedCentralCrossRef
102.
go back to reference Essouma M, Noubiap JJN. Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients. Biomark Res. 2015;3:24.PubMedPubMedCentralCrossRef Essouma M, Noubiap JJN. Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients. Biomark Res. 2015;3:24.PubMedPubMedCentralCrossRef
103.
go back to reference Kamat PK, Kalani A, Givvimani S, Sathnur PB, Tyagi SC, Tyagi N. Hydrogen sulfide attenuates neurodegeneration and neurovascular dysfunction induced by intracerebral-administered homocysteine in mice. Neuroscience. 2013;252:302–19.PubMedPubMedCentralCrossRef Kamat PK, Kalani A, Givvimani S, Sathnur PB, Tyagi SC, Tyagi N. Hydrogen sulfide attenuates neurodegeneration and neurovascular dysfunction induced by intracerebral-administered homocysteine in mice. Neuroscience. 2013;252:302–19.PubMedPubMedCentralCrossRef
105.
go back to reference Kedzierska M, Malinowska J, Glowacki R, Olas B, Bald E, Jeziorski A, et al. The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients. Mol Cell Biochem. 2011;355(1–2):193–9.PubMedCrossRef Kedzierska M, Malinowska J, Glowacki R, Olas B, Bald E, Jeziorski A, et al. The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients. Mol Cell Biochem. 2011;355(1–2):193–9.PubMedCrossRef
106.
go back to reference Lin J, Lee I-M, Song Y, Cook NR, Selhub J, Manson JE, et al. Plasma homocysteine and cysteine and risk of breast cancer in women. Cancer Res. 2010;70(6):2397–405.PubMedPubMedCentralCrossRef Lin J, Lee I-M, Song Y, Cook NR, Selhub J, Manson JE, et al. Plasma homocysteine and cysteine and risk of breast cancer in women. Cancer Res. 2010;70(6):2397–405.PubMedPubMedCentralCrossRef
107.
go back to reference Wu X, Zou T, Cao N, Ni J, Xu W, Zhou T, et al. Plasma homocysteine levels and genetic polymorphisms in folate metablism are associated with breast cancer risk in Chinese women. Hered Cancer Clin Pract. 2014;12(1):2.PubMedPubMedCentralCrossRef Wu X, Zou T, Cao N, Ni J, Xu W, Zhou T, et al. Plasma homocysteine levels and genetic polymorphisms in folate metablism are associated with breast cancer risk in Chinese women. Hered Cancer Clin Pract. 2014;12(1):2.PubMedPubMedCentralCrossRef
108.
go back to reference Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry. 2008;165(12):1543–50.PubMedPubMedCentralCrossRef Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry. 2008;165(12):1543–50.PubMedPubMedCentralCrossRef
109.
go back to reference Cho HJ, Lavretsky H, Olmstead R, Levin M, Oxman MN, Irwin MR. Prior depression history and deterioration of physical health in community-dwelling older adults—a prospective cohort study. Am J Geriatr Psychiatry. 2010;18(5):442–51.PubMedPubMedCentralCrossRef Cho HJ, Lavretsky H, Olmstead R, Levin M, Oxman MN, Irwin MR. Prior depression history and deterioration of physical health in community-dwelling older adults—a prospective cohort study. Am J Geriatr Psychiatry. 2010;18(5):442–51.PubMedPubMedCentralCrossRef
110.
go back to reference Monroe SM, Harkness KL. Life stress, the ‘kindling’ hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol Rev. 2005;112(2):417–45.PubMedCrossRef Monroe SM, Harkness KL. Life stress, the ‘kindling’ hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol Rev. 2005;112(2):417–45.PubMedCrossRef
111.
go back to reference Jim HSL, Small BJ, Minton S, Andrykowski M, Jacobsen PB. History of major depressive disorder prospectively predicts worse quality of life in women with breast cancer. Ann Behav Med. 2012;43(3):402–8.PubMedPubMedCentralCrossRef Jim HSL, Small BJ, Minton S, Andrykowski M, Jacobsen PB. History of major depressive disorder prospectively predicts worse quality of life in women with breast cancer. Ann Behav Med. 2012;43(3):402–8.PubMedPubMedCentralCrossRef
112.
go back to reference Irwin MR, Olmstead RE, Ganz PA, Haque R. Sleep disturbance, inflammation and depression risk in cancer survivors. Brain Behav Immun. 2013;30(Suppl):S58–67.PubMedCrossRef Irwin MR, Olmstead RE, Ganz PA, Haque R. Sleep disturbance, inflammation and depression risk in cancer survivors. Brain Behav Immun. 2013;30(Suppl):S58–67.PubMedCrossRef
113.
go back to reference Giese-Davis J, Wilhelm FH, Conrad A, Abercrombie HC, Sephton S, Yutsis M, et al. Depression and stress reactivity in metastatic breast cancer. Psychosom Med. 2006;68(5):675–83.PubMedCrossRef Giese-Davis J, Wilhelm FH, Conrad A, Abercrombie HC, Sephton S, Yutsis M, et al. Depression and stress reactivity in metastatic breast cancer. Psychosom Med. 2006;68(5):675–83.PubMedCrossRef
114.
go back to reference Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158(8):1252–7.PubMedCrossRef Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158(8):1252–7.PubMedCrossRef
115.
go back to reference Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsych. 2003;8(4):229–40. Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsych. 2003;8(4):229–40.
116.
go back to reference Berkey CS, Willett WC, Frazier AL, Rosner B, Tamimi RM, Rockett HRH, et al. Prospective study of adolescent alcohol consumption and risk of benign breast disease in young women. Pediatrics. 2010;125(5):e1081–7.PubMedPubMedCentralCrossRef Berkey CS, Willett WC, Frazier AL, Rosner B, Tamimi RM, Rockett HRH, et al. Prospective study of adolescent alcohol consumption and risk of benign breast disease in young women. Pediatrics. 2010;125(5):e1081–7.PubMedPubMedCentralCrossRef
117.
go back to reference Berkey CS, Tamimi RM, Rosner B, Frazier AL, Colditz GA. Young women with family history of breast cancer and their risk factors for benign breast disease. Cancer. 2012;118(11):2796–803.PubMedCrossRef Berkey CS, Tamimi RM, Rosner B, Frazier AL, Colditz GA. Young women with family history of breast cancer and their risk factors for benign breast disease. Cancer. 2012;118(11):2796–803.PubMedCrossRef
118.
go back to reference Ferrari P, Licaj I, Muller DC, Kragh Andersen P, Johansson M, Boeing H, et al. Lifetime alcohol use and overall and cause-specific mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. BMJ Open. 2014;4(7):e005245.PubMedPubMedCentralCrossRef Ferrari P, Licaj I, Muller DC, Kragh Andersen P, Johansson M, Boeing H, et al. Lifetime alcohol use and overall and cause-specific mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. BMJ Open. 2014;4(7):e005245.PubMedPubMedCentralCrossRef
119.
go back to reference Mathes RW, Malone KE, Daling JR, Davis S, Lucas SM, Porter PL, et al. Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomark Prev. 2008;17(11):3116–22.CrossRef Mathes RW, Malone KE, Daling JR, Davis S, Lucas SM, Porter PL, et al. Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomark Prev. 2008;17(11):3116–22.CrossRef
120.
go back to reference Li CI, Mathes RW, Malone KE, Daling JR, Bernstein L, Marchbanks PA, et al. Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women. Cancer Epidemiol Biomark Prev. 2009;18(7):2030–4.CrossRef Li CI, Mathes RW, Malone KE, Daling JR, Bernstein L, Marchbanks PA, et al. Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women. Cancer Epidemiol Biomark Prev. 2009;18(7):2030–4.CrossRef
121.
go back to reference Li CI, Mathes RW, Bluhm EC, Caan B, Cavanagh MF, Chlebowski RT, et al. Migraine history and breast cancer risk among postmenopausal women. J Clin Oncol. 2010;28(6):1005–10.PubMedPubMedCentralCrossRef Li CI, Mathes RW, Bluhm EC, Caan B, Cavanagh MF, Chlebowski RT, et al. Migraine history and breast cancer risk among postmenopausal women. J Clin Oncol. 2010;28(6):1005–10.PubMedPubMedCentralCrossRef
122.
go back to reference Winter AC, Rexrode KM, Lee I-M, Buring JE, Tamimi RM, Kurth T. Migraine and subsequent risk of breast cancer: a prospective cohort study. Cancer Causes Control. 2013;24(1):81–9.PubMedCrossRef Winter AC, Rexrode KM, Lee I-M, Buring JE, Tamimi RM, Kurth T. Migraine and subsequent risk of breast cancer: a prospective cohort study. Cancer Causes Control. 2013;24(1):81–9.PubMedCrossRef
123.
go back to reference Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interf Cytokine Res. 2015;35(1):1–16.CrossRef Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interf Cytokine Res. 2015;35(1):1–16.CrossRef
124.
go back to reference McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2006;15(6):1159–69.CrossRef McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2006;15(6):1159–69.CrossRef
125.
go back to reference Meng X, Zhong J, Liu S, Murray M, Gonzalez-Angulo AM. A new hypothesis for the cancer mechanism. Cancer Metastasis Rev. 2012;31(1–2):247–68.PubMedCrossRef Meng X, Zhong J, Liu S, Murray M, Gonzalez-Angulo AM. A new hypothesis for the cancer mechanism. Cancer Metastasis Rev. 2012;31(1–2):247–68.PubMedCrossRef
126.
go back to reference Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55(11):2698–708.PubMedCrossRef Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55(11):2698–708.PubMedCrossRef
127.
go back to reference Dupont WD, DL P. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146–51.PubMedCrossRef Dupont WD, DL P. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146–51.PubMedCrossRef
129.
go back to reference Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71(4):1258–65.PubMedCrossRef Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71(4):1258–65.PubMedCrossRef
130.
go back to reference Collins LC, Achacoso NA, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP, et al. Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol. 2007;20(11):1149–55.PubMedCrossRef Collins LC, Achacoso NA, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP, et al. Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol. 2007;20(11):1149–55.PubMedCrossRef
131.
132.
go back to reference Liu Y, Tamimi RM, Berkey CS, Willett WC, Collins LC, Schnitt SJ, et al. Intakes of alcohol and folate during adolescence and risk of proliferative benign breast disease. Pediatrics. 2012;129(5):e1192–8.PubMedPubMedCentralCrossRef Liu Y, Tamimi RM, Berkey CS, Willett WC, Collins LC, Schnitt SJ, et al. Intakes of alcohol and folate during adolescence and risk of proliferative benign breast disease. Pediatrics. 2012;129(5):e1192–8.PubMedPubMedCentralCrossRef
133.
go back to reference Baer HJ, Schnitt SJ, Connolly JL, Byrne C, Willett WC, Rosner B, et al. Early life factors and incidence of proliferative benign breast disease. Cancer Epidemiol Biomark Prev. 2005;14(12):2889–97.CrossRef Baer HJ, Schnitt SJ, Connolly JL, Byrne C, Willett WC, Rosner B, et al. Early life factors and incidence of proliferative benign breast disease. Cancer Epidemiol Biomark Prev. 2005;14(12):2889–97.CrossRef
134.
go back to reference Beaber EF, Malone KE, Tang M-TC, Barlow WE, Porter PL, Daling JR, et al. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomark Prev. 2014;23(5):755–64.CrossRef Beaber EF, Malone KE, Tang M-TC, Barlow WE, Porter PL, Daling JR, et al. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomark Prev. 2014;23(5):755–64.CrossRef
135.
136.
go back to reference Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol. 2011;8(11):669–76.PubMedCrossRef Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol. 2011;8(11):669–76.PubMedCrossRef
138.
go back to reference Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011;128(1):144–56.PubMedCrossRef Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011;128(1):144–56.PubMedCrossRef
139.
go back to reference Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer. 2008;123(4):933–41.PubMedCrossRef Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer. 2008;123(4):933–41.PubMedCrossRef
140.
go back to reference Rudolph A, Hein R, Lindström S, Beckmann L, Behrens S, Liu J, et al. Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. Endocr Relat Cancer. 2013;20(6):875–87.PubMedPubMedCentralCrossRef Rudolph A, Hein R, Lindström S, Beckmann L, Behrens S, Liu J, et al. Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. Endocr Relat Cancer. 2013;20(6):875–87.PubMedPubMedCentralCrossRef
141.
142.
go back to reference Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727–37 .W237-242PubMedPubMedCentralCrossRef Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727–37 .W237-242PubMedPubMedCentralCrossRef
143.
go back to reference Zhang XH-F, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19(23):6389–97.PubMedCrossRef Zhang XH-F, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19(23):6389–97.PubMedCrossRef
144.
go back to reference Debald M, Yeghiazaryan K, Cebioglu M, Kuhn W, Schild HH, Golubnitschaja O. ‘Suspect molecular signature’ in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention. EPMA J. 2013;4(1):22.PubMedPubMedCentralCrossRef Debald M, Yeghiazaryan K, Cebioglu M, Kuhn W, Schild HH, Golubnitschaja O. ‘Suspect molecular signature’ in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention. EPMA J. 2013;4(1):22.PubMedPubMedCentralCrossRef
145.
go back to reference Christodoulatos GS, Dalamaga M. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: quo vadis? World J Clin Oncol. 2014;5(2):71–81.PubMedPubMedCentralCrossRef Christodoulatos GS, Dalamaga M. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: quo vadis? World J Clin Oncol. 2014;5(2):71–81.PubMedPubMedCentralCrossRef
146.
go back to reference Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 2013;15(1):R4.PubMedPubMedCentralCrossRef Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 2013;15(1):R4.PubMedPubMedCentralCrossRef
147.
go back to reference Hayashi T, Asano H, Toyooka S, Tsukuda K, Soh J, Shien T, et al. DNA methylation status of REIC/Dkk-3 gene in human malignancies. J Cancer Res Clin Oncol. 2012;138(5):799–809.PubMedPubMedCentralCrossRef Hayashi T, Asano H, Toyooka S, Tsukuda K, Soh J, Shien T, et al. DNA methylation status of REIC/Dkk-3 gene in human malignancies. J Cancer Res Clin Oncol. 2012;138(5):799–809.PubMedPubMedCentralCrossRef
148.
go back to reference Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, et al. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Res Treat. 2010;122(3):699–710.PubMedCrossRef Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, et al. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Res Treat. 2010;122(3):699–710.PubMedCrossRef
149.
go back to reference Stötzer OJ, Lehner J, Fersching-Gierlich D, Nagel D, Holdenrieder S. Diagnostic relevance of plasma DNA and DNA integrity for breast cancer. Tumour Biol. 2014;35(2):1183–91.PubMedCrossRef Stötzer OJ, Lehner J, Fersching-Gierlich D, Nagel D, Holdenrieder S. Diagnostic relevance of plasma DNA and DNA integrity for breast cancer. Tumour Biol. 2014;35(2):1183–91.PubMedCrossRef
150.
go back to reference Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, et al. Circulating MMP2 and MMP9 in breast cancer—potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer. 2006;119(6):1403–11.PubMedCrossRef Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, et al. Circulating MMP2 and MMP9 in breast cancer—potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer. 2006;119(6):1403–11.PubMedCrossRef
151.
go back to reference Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, et al. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett. 2006;233(1):98–107.PubMedCrossRef Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, et al. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett. 2006;233(1):98–107.PubMedCrossRef
152.
go back to reference Slattery ML, John E, Torres-Mejia G, Stern M, Lundgreen A, Hines L, et al. Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One. 2013;8(5):e63165.PubMedPubMedCentralCrossRef Slattery ML, John E, Torres-Mejia G, Stern M, Lundgreen A, Hines L, et al. Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One. 2013;8(5):e63165.PubMedPubMedCentralCrossRef
153.
go back to reference Slattery ML, John EM, Stern MC, Herrick J, Lundgreen A, Giuliano AR, et al. Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat. 2013;140(3):587–601.PubMedPubMedCentralCrossRef Slattery ML, John EM, Stern MC, Herrick J, Lundgreen A, Giuliano AR, et al. Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat. 2013;140(3):587–601.PubMedPubMedCentralCrossRef
154.
go back to reference Slattery ML, John EM, Torres-Mejia G, Lundgreen A, Lewinger JP, Stern MC, et al. Angiogenesis genes, dietary oxidative balance and breast cancer risk and progression: the Breast Cancer Health Disparities Study. Int J Cancer. 2014;134(3):629–44.PubMedCrossRef Slattery ML, John EM, Torres-Mejia G, Lundgreen A, Lewinger JP, Stern MC, et al. Angiogenesis genes, dietary oxidative balance and breast cancer risk and progression: the Breast Cancer Health Disparities Study. Int J Cancer. 2014;134(3):629–44.PubMedCrossRef
155.
go back to reference Resler AJ, Malone KE, Johnson LG, Malkki M, Petersdorf EW, McKnight B, et al. Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. BMC Cancer. 2013;13:219.PubMedPubMedCentralCrossRef Resler AJ, Malone KE, Johnson LG, Malkki M, Petersdorf EW, McKnight B, et al. Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. BMC Cancer. 2013;13:219.PubMedPubMedCentralCrossRef
156.
go back to reference Melander O, Belting M, Manjer J, Maisel AS, Hedblad B, Engström G, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer. Cancer Epidemiol Biomark Prev. 2014;23(8):1672–6.CrossRef Melander O, Belting M, Manjer J, Maisel AS, Hedblad B, Engström G, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer. Cancer Epidemiol Biomark Prev. 2014;23(8):1672–6.CrossRef
157.
158.
go back to reference Warren Andersen S, Trentham-Dietz A, Gangnon RE, Hampton JM, Figueroa JD, Skinner HG, et al. Reproductive windows, genetic loci, and breast cancer risk. Ann Epidemiol. 2014;24(5):376–82.PubMedPubMedCentralCrossRef Warren Andersen S, Trentham-Dietz A, Gangnon RE, Hampton JM, Figueroa JD, Skinner HG, et al. Reproductive windows, genetic loci, and breast cancer risk. Ann Epidemiol. 2014;24(5):376–82.PubMedPubMedCentralCrossRef
159.
go back to reference Elebro K, Butt S, Dorkhan M, Jernström H, Borgquist S. Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort. Cancer Causes Control. 2014;25(8):945–57.PubMedCrossRef Elebro K, Butt S, Dorkhan M, Jernström H, Borgquist S. Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort. Cancer Causes Control. 2014;25(8):945–57.PubMedCrossRef
161.
go back to reference Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health. 2013;25(5):368–87.PubMedCrossRef Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health. 2013;25(5):368–87.PubMedCrossRef
162.
go back to reference Chlebowski RT. Nutrition and physical activity influence on breast cancer incidence and outcome. Breast. 2013;22(Suppl 2):S30–7.PubMedCrossRef Chlebowski RT. Nutrition and physical activity influence on breast cancer incidence and outcome. Breast. 2013;22(Suppl 2):S30–7.PubMedCrossRef
163.
go back to reference Steindorf K, Schmidt M, Ulrich C. Effects of physical activity on cancer risk and disease progression after cancer diagnosis. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2012;55(1):10–6.CrossRef Steindorf K, Schmidt M, Ulrich C. Effects of physical activity on cancer risk and disease progression after cancer diagnosis. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2012;55(1):10–6.CrossRef
165.
go back to reference Orlando LA, RR W, Beadles C, Himmel T, Buchanan AH, Powell KP, et al. Implementing family health history risk stratification in primary care: impact of guideline criteria on populations and resource demand. Am J Med Genet C: Semin Med Genet. 2014;166C(1):24–33.CrossRef Orlando LA, RR W, Beadles C, Himmel T, Buchanan AH, Powell KP, et al. Implementing family health history risk stratification in primary care: impact of guideline criteria on populations and resource demand. Am J Med Genet C: Semin Med Genet. 2014;166C(1):24–33.CrossRef
166.
168.
go back to reference Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, et al. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control. 2011;20(1):e2.PubMedCrossRef Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, et al. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control. 2011;20(1):e2.PubMedCrossRef
169.
go back to reference Truong T, Liquet B, Menegaux F, Plancoulaine S, Laurent-Puig P, Mulot C, et al. Breast cancer risk, nightwork, and circadian clock gene polymorphisms. Endocr Relat Cancer. 2014;21(4):629–38.PubMedCrossRef Truong T, Liquet B, Menegaux F, Plancoulaine S, Laurent-Puig P, Mulot C, et al. Breast cancer risk, nightwork, and circadian clock gene polymorphisms. Endocr Relat Cancer. 2014;21(4):629–38.PubMedCrossRef
170.
go back to reference Bracci M, Manzella N, Copertaro A, Staffolani S, Strafella E, Barbaresi M, et al. Rotating-shift nurses after a day off: peripheral clock gene expression, urinary melatonin, and serum 17-β-estradiol levels. Scand J Work Environ Health. 2014;40(3):295–304.PubMedCrossRef Bracci M, Manzella N, Copertaro A, Staffolani S, Strafella E, Barbaresi M, et al. Rotating-shift nurses after a day off: peripheral clock gene expression, urinary melatonin, and serum 17-β-estradiol levels. Scand J Work Environ Health. 2014;40(3):295–304.PubMedCrossRef
171.
go back to reference Mao Y, Fu A, Leaderer D, Zheng T, Chen K, Zhu Y. Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses. BMC Cancer. 2013;13:498.PubMedPubMedCentralCrossRef Mao Y, Fu A, Leaderer D, Zheng T, Chen K, Zhu Y. Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses. BMC Cancer. 2013;13:498.PubMedPubMedCentralCrossRef
172.
go back to reference Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett. 2014;342(1):9–18.PubMedCrossRef Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett. 2014;342(1):9–18.PubMedCrossRef
173.
174.
go back to reference Girschik J, Fritschi L, Erren TC, Heyworth J. Quantitative exposure metrics for sleep disturbance and their association with breast cancer risk. Cancer Causes Control. 2013;24(5):919–28.PubMedCrossRef Girschik J, Fritschi L, Erren TC, Heyworth J. Quantitative exposure metrics for sleep disturbance and their association with breast cancer risk. Cancer Causes Control. 2013;24(5):919–28.PubMedCrossRef
175.
go back to reference Malina C, Frigo S, Mathelin C. Sleep and breast cancer: is there a link? Gynécologie Obstétrique Fertil. 2013;41(2):105–9.CrossRef Malina C, Frigo S, Mathelin C. Sleep and breast cancer: is there a link? Gynécologie Obstétrique Fertil. 2013;41(2):105–9.CrossRef
176.
go back to reference Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomark Prev. 2009;18(1):74–9.CrossRef Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomark Prev. 2009;18(1):74–9.CrossRef
177.
go back to reference Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, et al. Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomark Prev. 2010;19(3):729–37.CrossRef Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, et al. Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomark Prev. 2010;19(3):729–37.CrossRef
178.
go back to reference Amadou A, Ferrari P, Muwonge R, Moskal A, Biessy C, Romieu I, et al. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obes Rev. 2013;14(8):665–78.PubMedCrossRef Amadou A, Ferrari P, Muwonge R, Moskal A, Biessy C, Romieu I, et al. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obes Rev. 2013;14(8):665–78.PubMedCrossRef
179.
go back to reference Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218–26.PubMedCrossRef Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218–26.PubMedCrossRef
180.
go back to reference Gallagher EJ, LeRoith D. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Curr Opin Endocrinol Diabetes Obes. 2013;20(5):485–94.PubMedCrossRef Gallagher EJ, LeRoith D. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Curr Opin Endocrinol Diabetes Obes. 2013;20(5):485–94.PubMedCrossRef
181.
go back to reference Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, et al. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer. 2014;23(2):134–40.CrossRef Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, et al. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer. 2014;23(2):134–40.CrossRef
182.
183.
go back to reference Naushad SM, Reddy CA, Kumaraswami K, Divyya S, Kotamraju S, Gottumukkala SR, et al. Impact of hyperhomocysteinemia on breast cancer initiation and progression: epigenetic perspective. Cell Biochem Biophys. 2014;68(2):397–406.PubMedCrossRef Naushad SM, Reddy CA, Kumaraswami K, Divyya S, Kotamraju S, Gottumukkala SR, et al. Impact of hyperhomocysteinemia on breast cancer initiation and progression: epigenetic perspective. Cell Biochem Biophys. 2014;68(2):397–406.PubMedCrossRef
184.
go back to reference Hansen MV, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, et al. The effect of MELatOnin on Depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial. BMJ Open. 2012;2(1):e000647.PubMedPubMedCentralCrossRef Hansen MV, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, et al. The effect of MELatOnin on Depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial. BMJ Open. 2012;2(1):e000647.PubMedPubMedCentralCrossRef
185.
go back to reference Hrushesky WJM, Grutsch J, Wood P, Yang X, E-Y O, Ansell C, et al. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther. 2009;8(4):387–97.PubMedCrossRef Hrushesky WJM, Grutsch J, Wood P, Yang X, E-Y O, Ansell C, et al. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther. 2009;8(4):387–97.PubMedCrossRef
186.
go back to reference Lemogne C, Consoli SM, Melchior M, Nabi H, Coeuret-Pellicer M, Limosin F, et al. Depression and the risk of cancer: a 15-year follow-up study of the GAZEL cohort. Am J Epidemiol. 2013;178(12):1712–20.PubMedCrossRef Lemogne C, Consoli SM, Melchior M, Nabi H, Coeuret-Pellicer M, Limosin F, et al. Depression and the risk of cancer: a 15-year follow-up study of the GAZEL cohort. Am J Epidemiol. 2013;178(12):1712–20.PubMedCrossRef
187.
go back to reference Nakaya N. Effect of psychosocial factors on cancer risk and survival. J Epidemiol Jpn Epidemiol Assoc. 2014;24(1):1–6.CrossRef Nakaya N. Effect of psychosocial factors on cancer risk and survival. J Epidemiol Jpn Epidemiol Assoc. 2014;24(1):1–6.CrossRef
189.
go back to reference Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M. Hormone replacement therapy and breast cancer in former users of oral contraceptives—the Norwegian Women and Cancer study. Int J Cancer. 2007;121(3):645–8.PubMedCrossRef Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M. Hormone replacement therapy and breast cancer in former users of oral contraceptives—the Norwegian Women and Cancer study. Int J Cancer. 2007;121(3):645–8.PubMedCrossRef
Metadata
Title
Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures
Authors
Olga Golubnitschaja
Manuel Debald
Kristina Yeghiazaryan
Walther Kuhn
Martin Pešta
Vincenzo Costigliola
Godfrey Grech
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5168-x

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine